Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGA4 | P13612 | 16/20 | 0.48 |
| ▸ | ITGB1 | P05556 | 6/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5152316 | 0.92 | ITGA4 (0.42) | ITGA4ITGB1SMN1; SMN2P2RX7MEN1 | |
| SCHEMBL5150154 | 0.89 | ITGA4 (0.47) | ITGA4ITGB1SMN1; SMN2 | |
| SCHEMBL6273679 | 0.87 | ITGA4 (0.47) | ITGA4ITGB1SMN1; SMN2P2RX7MEN1 | |
| SCHEMBL6955370 | 0.84 | ITGA4 (0.58) | ITGA4ITGB1 | |
| SCHEMBL6953576 | 0.82 | PTGER1 (0.36) | SMN1; SMN2 | |
| SCHEMBL6208698 | 0.81 | ITGA4 (0.46) | ITGA4ITGB1SMN1; SMN2 | |
| SCHEMBL5150111 | 0.81 | ITGA4 (0.46) | ITGA4ITGB1SMN1; SMN2 | |
| SCHEMBL5156521 | 0.81 | ITGA4 (0.45) | ITGA4ITGB1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL6208148 | 0.80 | ITGA4 (0.45) | ITGA4ITGB1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL5152611 | 0.79 | MAPT (0.44) | ITGA4ITGB1SMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070054909-A1 | VLA-4 inhibitor compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-03-08 | — | — | US | disclosed |
| US-7179819-B2 | VLA-4 inhibitor compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-02-20 | — | — | US | disclosed |
| US-20040229858-A1 | VLA-4 inhibitor compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-11-18 | — | — | US | disclosed |
| US-6756378-B2 | BENZYL -UREA, -THIOUREA, OR -GUANIDINE DERIVATIVES THAT INHIBIT THE BINDING OF LIGANDS TO ALPHA 4 BETA 1 INTEGRIN (VLA-4) | PHARMACOPEIA DRUG DISCOVERY, INC. | 2004-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054909-A1 | VLA-4 inhibitor compounds | VCAM1, ITGB4, ICAM1 | ITGA4 4/4885ITGB1 8/4885SMN1; SMN2 4245/4885 |
| US-20040229858-A1 | VLA-4 inhibitor compounds | VCAM1, ICAM1, ITGB4 | ITGA4 5/4885ITGB1 7/4885SMN1; SMN2 4213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.